Filing Details

Accession Number:
0001415889-24-005780
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-28 19:15:53
Reporting Period:
2024-02-26
Accepted Time:
2024-02-28 19:15:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1818794 Dyne Therapeutics Inc. DYN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1577014 P Jason Rhodes C/O Dyne Therapeutics, Inc.
830 Winter St.
Waltham MA 02451
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-02-26 136,312 $23.59 6,216,250 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-26 64,783 $23.98 6,151,467 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-26 20,205 $23.59 1,564,932 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-26 9,603 $23.98 1,555,329 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-26 11,736 $23.59 909,107 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-26 5,580 $23.98 903,527 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-27 272,923 $24.38 5,878,544 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-27 25,779 $24.68 5,852,765 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-27 40,455 $24.38 1,514,874 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-27 3,821 $24.68 1,511,053 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-27 23,505 $24.38 880,022 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-27 2,216 $24.68 877,806 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-28 152,244 $24.83 5,700,521 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-28 2,430 $25.25 5,698,091 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-28 22,567 $24.83 1,488,486 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-28 360 $25.25 1,488,126 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-28 13,109 $24.83 864,697 No 4 S Indirect See footnote
Common Stock Disposition 2024-02-28 210 $25.25 864,487 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Footnotes
  1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).
  3. The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.
  5. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.
  6. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The reporting person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
  7. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.
  8. The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.
  9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.
  10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.
  11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.
  12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.